Supernus Pharmaceuticals, INC Form 4 insider transactions

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, executed stock options and sold shares according to a pre-arranged trading plan.

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan on March 13, 2024.

Padmanabh P. Bhatt, a Supernus Pharmaceuticals executive, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Frank Mottola, SVP at Supernus Pharmaceuticals, settled performance share units and had shares withheld for tax obligations on February 28, 2024.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, settled performance share units, resulting in the acquisition and subsequent withholding of common stock for tax purposes.

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Charles W. Newhall III reports a transaction involving Supernus Pharmaceuticals common stock and restricted stock units.

Director Carrolee Barlow reports the acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 23, 2024.

Director Georges Gemayel reports the acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 23, 2024.

Director Frederick M. Hudson reports a transaction involving Supernus Pharmaceuticals common stock and restricted stock units.

Director John M. Siebert reports the acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 23, 2024.

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition and disposal of company stock and restricted stock units on February 23, 2024.

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, reported the acquisition and disposal of company stock on February 23, 2024, according to a Form 4 filing.

Timothy Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition of 2,500 shares and disposal of 1,314 shares of common stock on February 23, 2024, along with the disposal of 2,500 Restricted Stock Units.

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

Tami Tillotson Martin, a Senior VP at Supernus Pharmaceuticals, reported the acquisition of 1,250 shares of common stock and the disposal of 485 shares to cover tax obligations.